PE20081547A1 - THERAPEUTIC AGENTS CONTAINING AN INTERLEUKIN-6 ANTAGONIST AS AN ACTIVE INGREDIENT - Google Patents

THERAPEUTIC AGENTS CONTAINING AN INTERLEUKIN-6 ANTAGONIST AS AN ACTIVE INGREDIENT

Info

Publication number
PE20081547A1
PE20081547A1 PE2008000015A PE2008000015A PE20081547A1 PE 20081547 A1 PE20081547 A1 PE 20081547A1 PE 2008000015 A PE2008000015 A PE 2008000015A PE 2008000015 A PE2008000015 A PE 2008000015A PE 20081547 A1 PE20081547 A1 PE 20081547A1
Authority
PE
Peru
Prior art keywords
interleukin
antagonist
active ingredient
therapeutic agents
agents containing
Prior art date
Application number
PE2008000015A
Other languages
Spanish (es)
Inventor
Hitoshi Kohsaka
Nobuyuki Miyasaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Nat Univ Corp Tokyo Med & Dent
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39562504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081547(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Nat Univ Corp Tokyo Med & Dent, Riken filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20081547A1 publication Critical patent/PE20081547A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN COMPUESTO ANTAGONISTA DE LA INTERLEUCINA 6 (IL-6) TAL COMO UN ANTICUERPO CONTRA EL RECEPTOR IL-6 O UN ANTICUERPO CONTRA IL-6, UN ANTICUERPO MONOCLONAL, UN ANTICUERPO RECOMBINANTE, UN ANTICUERPO QUIMERICO, HUMANIZADO O HUMANO. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE UNA MIOPATIA INFLAMATORIA TAL COMO MIOSITIS MULTIPLE O DERMATOMIOSITISREFERRED TO AN ANTAGONIST COMPOUND OF INTERLEUKIN 6 (IL-6) SUCH AS AN ANTIBODY AGAINST IL-6 RECEPTOR OR AN ANTIBODY AGAINST IL-6, A MONOCLONAL ANTIBODY, A RECOMBINANT ANTIBODY, A CHIMERIC OR HUMANIZED ANTIBODY. SAID COMPOUND IS USEFUL IN THE TREATMENT OF AN INFLAMMATORY MYOPATHY SUCH AS MULTIPLE MYOSITIS OR DERMATOMYOSITIS

PE2008000015A 2006-12-27 2008-01-02 THERAPEUTIC AGENTS CONTAINING AN INTERLEUKIN-6 ANTAGONIST AS AN ACTIVE INGREDIENT PE20081547A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006351695A JP2010095445A (en) 2006-12-27 2006-12-27 Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient

Publications (1)

Publication Number Publication Date
PE20081547A1 true PE20081547A1 (en) 2009-01-18

Family

ID=39562504

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000015A PE20081547A1 (en) 2006-12-27 2008-01-02 THERAPEUTIC AGENTS CONTAINING AN INTERLEUKIN-6 ANTAGONIST AS AN ACTIVE INGREDIENT

Country Status (5)

Country Link
JP (1) JP2010095445A (en)
AR (1) AR064538A1 (en)
CL (1) CL2007003817A1 (en)
PE (1) PE20081547A1 (en)
WO (1) WO2008078715A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2011514B1 (en) 1997-03-21 2012-02-29 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
NZ534542A (en) 2002-02-14 2006-08-31 Chugai Pharmaceutical Co Ltd Antibody-containing solutions in which the formation of degradation products and insoluble particles during storage and freeze/thaw cycles is inhibited by adding a sugar and surfactant respectively
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005090405A1 (en) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha Subtype of humanized antibody against interleukin-6 receptor
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
EP4406615A2 (en) 2009-10-26 2024-07-31 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
CN104998254A (en) 2010-11-08 2015-10-28 基因技术公司 Subcutaneously administered anti-IL-6 receptor antibodies
MX363403B (en) 2013-07-04 2019-03-22 Hoffmann La Roche Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3630453B2 (en) * 1994-09-30 2005-03-16 中外製薬株式会社 A therapeutic agent for immature myeloma cells comprising an IL-6 receptor antibody as an active ingredient
PL186506B1 (en) * 1994-10-07 2004-01-30 Chugai Pharmaceutical Co Ltd Treatment of theumatoid artritis including an antagonist of il-6 as an active constituent
EP2011514B1 (en) * 1997-03-21 2012-02-29 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
PL201461B1 (en) * 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists
DE69934698T2 (en) * 1998-08-24 2007-10-04 Chugai Seiyaku K.K. MEDIUM FOR PREVENTING OR TREATING PANCREATITIS CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES AS ACTIVE COMPONENTS
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
MXPA04004671A (en) * 2001-11-14 2005-08-25 Johnson & Johnson Anti-il-6 antibodies, compositions, methods and uses.
AR048210A1 (en) * 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd A PREVENTIVE AGENT FOR VASCULITIS.

Also Published As

Publication number Publication date
AR064538A1 (en) 2009-04-08
JP2010095445A (en) 2010-04-30
CL2007003817A1 (en) 2008-06-27
WO2008078715A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
PE20081547A1 (en) THERAPEUTIC AGENTS CONTAINING AN INTERLEUKIN-6 ANTAGONIST AS AN ACTIVE INGREDIENT
RU2010117171A (en) THERAPEUTIC AGENTS USED AGAINST REACTION TRANSPLANT AGAINST THE OWNER, CONTAINING AN INTERLEUKIN-6 RECEPTOR INHIBITOR AS AN ACTIVE INGREDIENT
EA201170676A1 (en) AGONISTS OF RECEPTOR MELANOCORTIN
CY1123701T1 (en) PESTICIDAL COMPOSITIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHOD AND USES THEREOF
RU2010127291A (en) THERAPEUTIC AGAINST ITCH
EA201991919A1 (en) Parasiticidal Oral Veterinary Compositions Including Systemically Acting Active Agents, Methods and Application of These Compositions and Methods
MX2009006304A (en) Novel oxadiazole compounds.
TW200626068A (en) Active compounds for seed treatment
ECSP066991A (en) 3- (4-HETEROARILCICLOHEXILAMINO) CYCLOPENTANOCARBOXAMIDS AS CHEMIOKIN RECEPTORS MODULATORS
MY156702A (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
ECSP067121A (en) 3-AMINOCICLOPENTANOCARBOXAMIDS AS CHEMIOKIN RECEPTORS MODULATORS
UA108641C2 (en) PARASITICID COMPOSITION CONTAINING FOUR ACTIVE AGENTS AND METHOD OF APPLICATION
UA109173C2 (en) COMPOSITION CONTAINING FUNGICIDUM STRAIN AND CHEMICAL COMPOUND
RS51954B (en) Crystalline modifications to pyraclostrobin
UA110013C2 (en) APPLICATION OF THE COMPOSITION FOR THE TREATMENT OF BALL-MARI-HERE AND THE RELATED DISORDERS
DE602005023197D1 (en) -MUSCARINREZEPTORS
EA200870292A1 (en) COMPOUNDS BASED ON IMIDAZOL, COMPOSITIONS CONTAINING THEM, AND METHODS OF THEIR APPLICATION
EA200602242A1 (en) 3-AMINOCYCLOPENTANCARBOXAMIDES AS CHEMOKINE RECEPTOR MODULATORS
EA201071040A1 (en) NEW DERIVATIVES 1-BENZYL-3-HYDROXYMETHYLINDASOL AND THEIR APPLICATION IN THE TREATMENT OF DISEASES CAUSED BY EXPRESSION OF MCP-1, CX3CR1 And P40
EA201492023A1 (en) REGULATORS OF THE COMPLEX WAY AND THEIR APPLICATION
EA200970532A1 (en) FUMARATE SALT (ALPHA S, BETA R) -6-BRUM-ALPHA- [2- (DIMETHYLAMINO) ETHYL] -2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-HINOLINETHANOL
EA201001230A1 (en) PESTICIDAL MIXTURES
ATE478856T1 (en) SPIROBENZODIOXOLS AND THEIR USE AS CB1 ANTAGONISTS
EA201400165A1 (en) PARTICLES BASED ON POLYACRYLATE THAT CONTAIN AN ACTIVE CONNECTION
CY1114163T1 (en) METHODS OF USE OF ANGIOPYCIN COMPETITORS WITH CARBON CYCLOTHERIC AGENTS TO REDUCE CARDIOTOXICITY AND / OR IMPROVEMENT

Legal Events

Date Code Title Description
FA Abandonment or withdrawal